Novozymes’ rAlbumin supports faster time to market for Neomend adhesion barrier sealant

NOTTINGHAM, UK – May 2, 2012 – Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, has announced that its recombinant human albumin (rAlbumin), Albucult^®, is being used by Neomend in the company’s Progel^® Adhesion Barrier Sealant product which has recently received the European Union CE mark. Albucult, used as a key component in medical device applications, helps to facilitate regulatory compliance and enables a faster time to market due to its stable, safe and animal-free composition. The product’s high purity can help manufacturers manage and reduce both commercial and regulatory risk where source variability and safety profile are important considerations in the commercialization of drug and medical device products.  

David Renzi, Neomend’s President and CEO, comments: “Novozymes has an extensive understanding of the regulatory pressures its customers are facing and its quality-assured, consistent biopharmaceutical components make the company an ideal partner for Neomend. The Progel Adhesion Barrier Sealant CE mark is a vital milestone as it will enable us to help surgeons in Europe effectively prevent adhesions and its associated complications.”

Neomend uses Novozymes’ Albucult in its Progel Adhesion Barrier Sealant, a product that has been developed as a hydrogel adhesion barrier sealant that can be sprayed onto general visceral organs during open and laparoscopic surgery to help prevent post-operative adhesions. The addition of a CE mark will help Neomend to expand the distribution of its latest sealant across Europe. This is the second Neomend sealant that incorporates Albucult with the product already being used successfully in the company’s ProGEL^® PLATINUM surgical sealant.

“Novozymes is delighted that Albucult is being used as a key component in another CE marked medical device”, says Dermot Pearson, Marketing Director, Novozymes Biopharma. “It is a testament to the unique advantages conferred by the product and demonstrates our commitment to supporting customers throughout their regulatory process. We have a dedicated regulatory affairs team that monitors regulatory changes and trends, while working closely with relevant trade organizations to offer customers current, fast and efficient support for product registration.”

The use of Albucult as a key ingredient in medical devices offers a range of performance and quality benefits for medical applications not possible with animal-derived ingredients including an exceptional purity profile and sustainability of supply. Novozymes’ Albucult also ensures batch-to-batch consistency to reduce processing and testing times to drive product efficiency for customers looking for a compliant albumin alternative.

To learn more about Novozymes’ Albucult, please visit www.biopharma.novozymes.com.

To find out more about Neomend, please visit www.neomend.com.

About Neomend, Inc.

Neomend, based in Irvine, California, is a private company focused on the design, development and commercialization of surgical sealants and adhesion prevention products derived from the ProGEL technology platform. The company has a direct sales force of 30 people in the U.S. and holds 29 issued U.S. patents in chemical composition and delivery applicators. For more information, visit www.Neomend.com or call 949-916-1630.

About Novozymes

Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries, we create tomorrow’s industrial biosolutions, improving our customers' business and the use of our planet's resources.

With over 700 products used in 130 countries, Novozymes’ bioinnovations improve industrial performance and safeguard the world’s resources by offering superior and sustainable solutions for tomorrow’s ever-changing marketplace. Read more at www.novozymes.com.

Novozymes Biopharma supplies R-Tech Ueno with Albucult® for use in unique dry eye therapy

New treatment will be the first of its kind to utilize the benefits of Novozymes’ recombinant human albumin
NOTTINGHAM, UK – November 15, 2011 – Novozymes Biopharma, part of Novozymes A/S world leader in bioinnovation, has announced that its recombinant human albumin, Albucult®, has been selected by R-Tech Ueno for use in a unique treatment for dry eye syndrome. R-Tech Ueno is a global pharmaceutical company specializing in the fields of ophthalmology and dermatology. The Japan-based company will utilize Albucult as a key component in its new therapy which will be the first of its kind developed for the treatment of severe and moderate dry eye conditions. Albucult is manufactured by Novozymes’ long-term technology partner Kaketsuken based in Kumamoto, Japan and marketed by Novozymes world-wide.

Dr Yukihiko Mashima, President of R-Tech Ueno, comments: “Novozymes’ and Kaketsuken’s commitment to supplying products that enhance the safety profile and quality of their partners’ medicines makes them the ideal collaborators for us to work with. Novozymes has a wealth of experience of biomaterials and sets the benchmark for recombinant human albumin.”

Prevalence of dry eye syndrome continues to increase, with the condition having the highest rate of diagnosis of all ophthalmic disorders. As an active ingredient, Albucult® confers a range of unique advantages to the development of R-Tech Ueno’s new therapy including an exceptional purity profile and excellent batch-to-batch consistency, which is not possible with animal-derived ingredients.
Dermot Pearson, Marketing Director at Novozymes Biopharma, comments: “Novozymes is delighted that R-Tech Ueno has selected Albucult for use in the development of this innovative new treatment. The partnership demonstrates our commitment to supplying customers with quality biomaterials that reduce operational and regulatory complexity and minimize manufacturing risk.”

The use of Albucult in R-Tech Ueno’s therapy and other drugs can help to optimize pathways through regulatory approval procedures and improve time–to-market. Albucult also delivers unprecedented performance benefits to protein therapeutics and medical devices while ensuring security of supply and consistent quality. This can drive product development efficiency for customers looking for a compliant albumin alternative.

For further information on Novozymes Biopharma’s Albucult, please visit www.biopharma.novozymes.com

###
About Novozymes
Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries, we create tomorrow’s industrial biosolutions, improving our customers' business and the use of our planet's resources.

With over 700 products used in 130 countries, Novozymes’ bioinnovations improve industrial performance and safeguard the world’s resources by offering superior and sustainable solutions for tomorrow’s ever-changing marketplace. Read more at www.novozymes.com.


Contact:
Novozymes Biopharma:
Sally Vernon, Customer Communications Manager
SYKE@novozymes.com
Tel. +44 115 955 3355

Novozymes enters into an exclusive supplier agreement to supply Recombumin for Type 2 Diabetes drug

NOTTINGHAM, UK – September 30, 2011 – Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, has announced that it has concluded an exclusive supply agreement with ConjuChem LLC of Los Angeles, California. Novozymes will supply its recombinant human albumin, Recombumin, for use in the development of a new GLP-1 analog in Phase 2 testing for Type 2 diabetes. The use of Recombumin in the development of the product potentially significantly reduces dosing frequency, allowing patients to self-inject once per week instead of once or twice daily.

“This supply agreement is a great example of using Novozymes’ Recombumin as a vehicle for extending the half-life of peptides in drug delivery applications,” said Thomas Videbæk, Executive Vice President of Novozymes’ BioBusiness. “Also the agreement for this new drug will potentially pave the way for the use of Recombumin in other peptide-based therapies.”

Novozymes Biopharma secures business innovation award

Company recognized for its commitment to pushing back scientific frontiers and developing solutions that enhance the manufacture of medical devices and pharmaceuticals

NOTTINGHAM, UK – July 21, 2011 – Novozymes Biopharma, part of Novozymes A/S, world leader in bioinnovation, received the 2011 Nottingham Evening Post
(NEP) Business Award in the business innovation category, for its innovative recombinant human albumin range. The company has been recognized for its outstanding contribution to pushing back scientific frontiers by developing innovative, process improving solutions for the medical device and pharmaceutical manufacturing industries. The NEP business awards are designed to reward organizations in the region for setting new benchmarks in their industries and the company is delighted to add this accolade to its growing collection of awards.

Novozymes Biopharma to present latest advances in drug delivery technology at Controlled Release Society Meeting

NOTTINGHAM, UK – July 6, 2011 – Novozymes Biopharma, part of Novozymes A/S, world leader in bioinnovation, today announced two new scientific posters to be presented at the 2011 Controlled Release Society (CRS) meeting and exposition, July 30–August 3, Maryland, USA. The posters highlight the formulation and stabilization capabilities of recombinant albumin (rAlbumin) to safeguard the integrity of protein drug substances as well as the potential for combining hyaluronic acid (HA) and diclofenac sodium to extend drug release in osteoarthritis applications. For more information or to request a copy of the scientific posters, please visit booth #301 at the 2011 CRS meeting or www.biopharma.novozymes.com.